SDIX adds nine new polyclonal antibodies to IVD reagents portfolio

SDIX (NASDAQ: SDIX), a leading provider of In Vitro Diagnostic (IVD) reagents, announced the addition of nine new polyclonal antibodies to its product line for the IVD market while exhibiting at AACC last week. These products include Apo A1, Lp(a), HPT, CER, IgM, IgG(Fc), IgA, C3 and C4. The antibodies can be customized for in vitro diagnostics and will be available as antisera and in fractionated forms. The nine new products complement the existing SDIX IVD product line, which includes Troponin I, Strep A, CRP, ApoB and Albumin.

These antibodies are used by most of the primary IVD assay companies and are estimated to represent a market of nearly $40M, according to analysis based on a Kalorama Information Report published in 2008. Immunoassay companies are currently faced with multiple challenges as they develop and expand their assay portfolio, and SDIX believes that it is strongly positioned to assist with these issues. These challenges include product quality, timely availability, supplier's scalability, lot-to-lot consistency and platform compatibility. SDIX intends to utilize its custom development capabilities to deliver products which are superior in performance to those available in the general catalog market.

"Customizing antibodies for our customers' specific assays is one of SDIX's core competencies. In addition to customization, we provide customers the benefit of reagent supply managed to their specific technical and business requirements," said Paul Dany K., SDIX's IVD Product Manager. He continued, "We anticipate that these new products will open up opportunities with new and existing customers in the near future."